REFERENCES
1. McCann H, Cartwright H, Halliday GM. Neuropathology of α-synuclein propagation and braak hypothesis. Mov Disord. 2016;31:152-60.
2. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197-211.
3. Rey NL, Steiner JA, Maroof N, et al. Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease. J Exp Med. 2016;213:1759-78.
4. Van Den Berge N, Ferreira N, Gram H, et al. Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats. Acta Neuropathol. 2019;138:535-50.
5. Ferreira N, Gonçalves NP, Jan A, et al. Trans-synaptic spreading of alpha-synuclein pathology through sensory afferents leads to sensory nerve degeneration and neuropathic pain. Acta Neuropathol Commun. 2021;9:31.
6. Andersen KB, Krishnamurthy A, Just MK, et al. Sympathetic and parasympathetic subtypes of body-first Lewy body disease observed in postmortem tissue from prediagnostic individuals. Nat Neurosci. 2025;28:925-36.
7. Bernis ME, Babila JT, Breid S, Wüsten KA, Wüllner U, Tamgüney G. Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. Acta Neuropathol Commun. 2015;3:75.
8. Tardivel M, Bégard S, Bousset L, et al. Tunneling nanotube (TNT)-mediated neuron-to neuron transfer of pathological Tau protein assemblies. Acta Neuropathol Commun. 2016;4:117.
9. Rostami J, Holmqvist S, Lindström V, et al. Human astrocytes transfer aggregated alpha-synuclein via tunneling nanotubes. J Neurosci. 2017;37:11835-53.
10. Abounit S, Bousset L, Loria F, et al. Tunneling nanotubes spread fibrillar α-synuclein by intercellular trafficking of lysosomes. EMBO J. 2016;35:2120-38.
11. Chakraborty R, Nonaka T, Hasegawa M, Zurzolo C. Tunnelling nanotubes between neuronal and microglial cells allow bi-directional transfer of α-Synuclein and mitochondria. Cell Death Dis. 2023;14:329.
12. Scheiblich H, Dansokho C, Mercan D, et al. Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes. Cell. 2021;184:5089-106.e21.
13. Scheiblich H, Eikens F, Wischhof L, et al. Microglia rescue neurons from aggregate-induced neuronal dysfunction and death through tunneling nanotubes. Neuron. 2024;112:3106-25.e8.
14. Danzer KM, Kranich LR, Ruf WP, et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener. 2012;7:42.
15. Kurzawa-Akanbi M, Tammireddy S, Fabrik I, et al. Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders. Acta Neuropathol. 2021;142:961-84.
16. Ishiguro Y, Tsunemi T, Shimada T, et al. Extracellular vesicles contain filamentous alpha-synuclein and facilitate the propagation of Parkinson’s pathology. Biochem Biophys Res Commun. 2024;703:149620.
17. Du TT, Wang L, Duan CL, et al. GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A. Autophagy. 2015;11:1803-20.
18. Muñoz SS, Petersen D, Marlet FR, Kücükköse E, Galvagnion C. The interplay between Glucocerebrosidase, α-synuclein and lipids in human models of Parkinson’s disease. Biophys Chem. 2021;273:106534.
19. Murphy KE, Gysbers AM, Abbott SK, et al. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease. Brain. 2014;137:834-48.
20. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146:37-52.
21. Zunke F, Moise AC, Belur NR, et al. Reversible conformational conversion of α-synuclein into toxic assemblies by glucosylceramide. Neuron. 2018;97:92-107.e10.
22. Taguchi YV, Liu J, Ruan J, et al. Glucosylsphingosine promotes α-synuclein pathology in mutant GBA-associated Parkinson’s disease. J Neurosci. 2017;37:9617-31.
23. Franck L, Hahnefeld L, Valek L, et al. Elevated hexosylceramides in Parkinson’s disease cause gene upregulations in neurons mimicking responses to pathogens. NPJ Parkinsons Dis. 2025;11:268.
24. Wang R, Sun H, Cao Y, et al. Glucosylceramide accumulation in microglia triggers STING-dependent neuroinflammation and neurodegeneration in mice. Sci Signal. 2024;17:eadk8249.
25. Jacquemyn J, Marriott B, Chang J, et al. Glucosylceramide-induced ectosomes propagate pathogenic α-synuclein in Parkinson’s disease. Nat Cell Biol. 2026;28:492-506.
26. Brodeur A, Migneault F, Lanoie M, et al. Apoptotic exosome-like vesicles transfer specific and functional mRNAs to endothelial cells by phosphatidylserine-dependent macropinocytosis. Cell Death Dis. 2023;14:449.
27. Zhang C, Yang Z, Zhou P, et al. Phosphatidylserine-exposing tumor-derived microparticles exacerbate coagulation and cancer cell transendothelial migration in triple-negative breast cancer. Theranostics. 2021;11:6445-60.
28. Wei X, Liu C, Wang H, et al. Surface phosphatidylserine is responsible for the internalization on microvesicles derived from hypoxia-induced human bone marrow mesenchymal stem cells into human endothelial cells. PLoS One. 2016;11:e0147360.
29. Abdulsahib WK, Mustafa WW, Jyothi SR, et al. Unveiling exosomes and microvesicles in Parkinson’s disease: mechanistic insights into cell death pathways and therapeutic potential. Mol Neurobiol. 2025;63:187.
30. Cable J, Witwer KW, Coffey RJ, et al. Exosomes, microvesicles, and other extracellular vesicles-a Keystone Symposia report. Ann N Y Acad Sci. 2023;1523:24-37.
31. Alvarez-Erviti L, Seow Y, Schapira AH, et al. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis. 2011;42:360-7.
32. Shi M, Liu C, Cook TJ, et al. Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease. Acta Neuropathol. 2014;128:639-50.
33. Emmanouilidou E, Vekrellis K. Exocytosis and spreading of normal and aberrant α-synuclein. Brain Pathol. 2016;26:398-403.
34. Papadopoulos VE, Nikolopoulou G, Antoniadou I, et al. Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson’s disease. Hum Mol Genet. 2018;27:1696-710.
35. Jiang C, Hopfner F, Berg D, et al. Validation of α-synuclein in L1CAM-immunocaptured exosomes as a biomarker for the stratification of Parkinsonian syndromes. Mov Disord. 2021;36:2663-9.
36. Jiang C, Hopfner F, Katsikoudi A, et al. Serum neuronal exosomes predict and differentiate Parkinson’s disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry. 2020;91:720-9.
37. Niu M, Li Y, Li G, et al. A longitudinal study on α-synuclein in plasma neuronal exosomes as a biomarker for Parkinson’s disease development and progression. Eur J Neurol. 2020;27:967-74.
38. Mahapatra A, Malingen SA, Rangamani P. Interplay between cortical adhesion and membrane bending regulates the formation of microparticles. Soft Matter. 2026;22:1569-82.
39. Sun M, Xue X, Li L, et al. Ectosome biogenesis and release processes observed by using live-cell dynamic imaging in mammalian glial cells. Quant Imaging Med Surg. 2021;11:4604-16.
40. Bayati A, Banks E, Han C, et al. Rapid macropinocytic transfer of α-synuclein to lysosomes. Cell Rep. 2022;40:111102.
41. Park JY, Kim KS, Lee SB, et al. On the mechanism of internalization of alpha-synuclein into microglia: roles of ganglioside GM1 and lipid raft. J Neurochem. 2009;110:400-11.
42. Lai RC, Lim SK. Membrane lipids define small extracellular vesicle subtypes secreted by mesenchymal stromal cells. J Lipid Res. 2019;60:318-22.
43. Matsumura S, Minamisawa T, Suga K, et al. Subtypes of tumour cell-derived small extracellular vesicles having differently externalized phosphatidylserine. J Extracell Vesicles. 2019;8:1579541.
44. Skotland T, Llorente A, Sandvig K. Lipids in extracellular vesicles: what can be learned about membrane structure and function? Cold Spring Harb Perspect Biol 2023;15:a041415.
45. Xie YX, Naseri NN, Fels J, et al. Lysosomal exocytosis releases pathogenic α-synuclein species from neurons in synucleinopathy models. Nat Commun. 2022;13:4918.
46. Tsunemi T, Perez-Rosello T, Ishiguro Y, et al. Increased lysosomal exocytosis induced by lysosomal Ca2+ channel agonists protects human dopaminergic neurons from α-synuclein toxicity. J Neurosci. 2019;39:5760-72.
47. Dutta S, Hornung S, Kruayatidee A, et al. α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson’s disease from multiple system atrophy. Acta Neuropathol. 2021;142:495-511.
48. Ohmichi T, Mitsuhashi M, Tatebe H, Kasai T, Ali El-Agnaf OM, Tokuda T. Quantification of brain-derived extracellular vesicles in plasma as a biomarker to diagnose Parkinson’s and related diseases. Parkinsonism Relat Disord. 2019;61:82-7.
49. Sepúlveda D, Cisternas-Olmedo M, Arcos J, Nassif M, Vidal RL. Contribution of autophagy-lysosomal pathway in the exosomal secretion of alpha-synuclein and its impact in the progression of Parkinson’s disease. Front Mol Neurosci. 2022;15:805087.
50. Magalhaes J, Gegg ME, Migdalska-Richards A, Schapira AH. Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons. Sci Rep. 2018;8:1385.
51. Fois G, Hobi N, Felder E, et al. A new role for an old drug: ambroxol triggers lysosomal exocytosis via pH-dependent Ca2+ release from acidic Ca2+ stores. Cell Calcium. 2015;58:628-37.
52. Franck L, Valek L, Hahnefeld L, et al. Modest improvement of metabolic and behavioral deficits with long-term ambroxol treatment in a Pink1-/-SNCAA53T double mutant mouse model of Parkinson’s disease. Acta Pharmacol Sin. 2026;47:836-59.
53. Wu KM, Xu QH, Liu YQ, et al. Neuronal FAM171A2 mediates α-synuclein fibril uptake and drives Parkinson’s disease. Science. 2025;387:892-900.
54. Mao X, Ou MT, Karuppagounder SS, et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. 2016;353:aah3374.
55. Zhang Q, Duan Q, Gao Y, et al. Cerebral microvascular injury induced by lag3-dependent α-synuclein fibril endocytosis exacerbates cognitive impairment in a mouse model of α-synucleinopathies. Adv Sci. 2023;10:e2301903.
56. Ambrosi G, Ghezzi C, Zangaglia R, Levandis G, Pacchetti C, Blandini F. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson’s disease cells. Neurobiol Dis. 2015;82:235-42.
57. Colucci F, Avenali M, De Micco R, et al. Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson’s disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol. BMJ Neurol Open. 2023;5:e000535.
58. Stuendl A, Kunadt M, Kruse N, et al. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies. Brain. 2016;139:481-94.
59. Ugalde CL, Gordon SE, Shambrook M, et al. An intact membrane is essential for small extracellular vesicle-induced modulation of α-synuclein fibrillization. J Extracell Vesicles. 2020;10:e12034.
60. Ulmer TS, Bax A, Cole NB, Nussbaum RL. Structure and dynamics of micelle-bound human alpha-synuclein. J Biol Chem. 2005;280:9595-603.
